Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 2/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7448778 | 1.00 | MME (0.43) | MMETSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL2371712 | 1.00 | MME (0.43) | MMETSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL2405013 | 1.00 | MME (0.43) | MMETSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL5659137 | 1.00 | MME (0.43) | MMETSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL12814592 | 1.00 | MME (0.43) | MMETSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL572230 | 0.89 | TSHR (0.49) | MMETSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL482185 | 0.89 | TSHR (0.49) | MMETSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL482184 | 0.89 | TSHR (0.49) | MMETSHRPOLBSMN1; SMN2KDM4E | |
| SCHEMBL3404489 | 0.88 | BTK (0.44) | MMETSHRSMN1; SMN2KDM4EMAPT | |
| SCHEMBL2370831 | 0.88 | BTK (0.44) | MMETSHRSMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802711-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2688866-A1 | TRPV1 ANTAGONISTS | AbbVie Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012134943-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120245163-A1 | TRPV1 Antagonists | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1296938-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | MME 7/4885TSHR 2123/4885POLB 3632/4885 |
| US-20120245163-A1 | TRPV1 Antagonists | TRPV1, TRPV3, TRPV6 | MME 1442/4885TSHR 2103/4885POLB 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.